研究者業績

上田 洋司

Hiroshi Ageta

基本情報

所属
藤田医科大学 総合医科学研究所 難病治療学 講師
学位
理学博士(九州大学)

研究者番号
40416649
J-GLOBAL ID
201101022480531310
researchmap会員ID
B000004067

外部リンク

2001年 九州大学大学院医学系研究科修了、理学博士。2001~2005年 三菱化学生命科学研究所・記憶形成精神疾患研究グループ・特別研究員。 2005~2009年 三菱化学生命科学研究所・分子加齢医学研究グループ・副主任研究員。2009年4~現在 藤田保健衛生大学・助教。2019年10月 藤田医科大学・講師。

論文

 34
  • Hiroshi Ageta, Yoshihisa Shimada, Tadahiro Nagaoka, Kazuki Takenaka, Yusuke Yoshioka, Kohtaro Konno, Ryosuke Amemiya, Kumiko Nagase, Keisuke Hitachi, Takanori Onouchi, Masahiko Watanabe, Takahiro Ochiya, Kunihiro Tsuchida
    Scientific reports 15(1) 43802-43802 2025年12月15日  
    Small extracellular vesicles (sEVs) mediate cell-to-cell communication by carrying RNAs and proteins. Ubiquitin-like 3 (UBL3) functions as a posttranslational modification factor, regulating protein sorting to sEVs. Programmed cell death ligand 1 (PD-L1) binds to programmed cell death 1 (PD-1) on immune cells, suppressing their function. Although immune checkpoint inhibitors, anti-PD-L1 and anti-PD-1 antibodies, have improved cancer treatment, efficacy remains limited (~ 25%). Per recent studies, PD-L1-containing sEVs are elevated in cancer patients, contributing to impaired immunotherapy responses. Herein, we discovered that PD-L1 is modified by UBL3 and that its sorting to sEVs is regulated by UBL3. Furthermore, we found that statins, commonly prescribed for hypercholesterolemia, inhibit UBL3 modification, thereby reducing PD-L1 sorting to sEVs. Among patients with a high tumor proportion score, serum levels of PD-L1-containing sEVs were significantly lower in those using statins. Consistently, bioinformatic analysis revealed that UBL3 and PD-L1 expression levels affect lung cancer survival. Integrating statins into existing combination therapies may therefore offer a promising strategy to enhance immunotherapy efficacy.
  • Natsumi Ageta-Ishihara, Yugo Fukazawa, Fumiko Arima-Yoshida, Hiroyuki Okuno, Yuichiro Ishii, Keizo Takao, Kohtarou Konno, Kazuto Fujishima, Hiroshi Ageta, Hiroyuki Hioki, Kunihiro Tsuchida, Yoshikatsu Sato, Mineko Kengaku, Masahiko Watanabe, Ayako M Watabe, Toshiya Manabe, Tsuyoshi Miyakawa, Kaoru Inokuchi, Haruhiko Bito, Makoto Kinoshita
    Cell reports 115352-115352 2025年2月27日  
    Transient memories are converted to persistent memories at the synapse and circuit/systems levels. The synapse-level consolidation parallels electrophysiological transition from early- to late-phase long-term potentiation of synaptic transmission (E-/L-LTP). While glutamate signaling upregulations coupled with dendritic spine enlargement are common underpinnings of E-LTP and L-LTP, synaptic mechanisms conferring persistence on L-LTP remain unclear. Here, we show that L-LTP induced at the perforant path-hippocampal dentate gyrus (DG) synapses accompanies cytoskeletal remodeling that involves actin and the septin subunit SEPT3. L-LTP in DG neurons causes fast spine enlargement, followed by SEPT3-dependent smooth endoplasmic reticulum (sER) extension into enlarged spines. Spines containing sER show greater Ca2+ responses upon synaptic input and local synaptic activity. Consistently, Sept3 knockout in mice (Sept3-/-) impairs memory consolidation and causes a scarcity of sER-containing spines. These findings indicate a concept that sER extension into active spines serves as a synaptic basis of memory consolidation.
  • Yuka Terada, Kumi Obara, Yusuke Yoshioka, Takahiro Ochiya, Haruhiko Bito, Kunihiro Tsuchida, Hiroshi Ageta, Natsumi Ageta-Ishihara
    Biology open 13(11) 2024年11月15日  
    Exosomes are small extracellular vesicles (sEVs) secreted via multivesicular bodies (MVBs)/late endosomes and mediators of cell-cell communication. We previously reported a novel post-translational modification by ubiquitin-like 3 (UBL3). UBL3 is localized in MVBs and the plasma membrane and released outside as sEVs, including exosomes. Approximately 60% of proteins sorted in sEVs are affected by UBL3 and localized in various organelles, the plasma membrane, and the cytosol, suggesting that its dynamic movement in the cell before entering the MVBs. To examine the intracellular dynamics of UBL3, we constructed a sophisticated visualization system via fusing fluorescent timers that changed from blue to red form over time with UBL3 and by its expression under Tet-on regulation. Intriguingly, we found that after synthesis, UBL3 was initially distributed within the cytosol. Subsequently, UBL3 was localized to MVBs and the plasma membrane and finally showed predominant accumulation in MVBs. Furthermore, by super-resolution microscopy analysis, UBL3 was found to be associated with one of its substrates, α-tubulin, in the cytosol, and the complex was subsequently transported to MVBs. This spatiotemporal visualization system for UBL3 will form a basis for further studies to elucidate when and where UBL3 associates with its substrates/binding proteins before localization in MVBs.
  • Hiroshi Ageta, Tomoki Nishioka, Hisateru Yamaguchi, Kunihiro Tsuchida, Natsumi Ageta-Ishihara
    Molecular brain 17(1) 57-57 2024年8月15日  
    Discovery of novel post-translational modifications provides new insights into changes in protein function, localization, and stability. They are also key elements in understanding disease mechanisms and developing therapeutic strategies. We have previously reported that ubiquitin-like 3 (UBL3) serves as a novel post-translational modifier that is highly expressed in the cerebral cortex and hippocampus, in addition to various other organs, and that 60% of proteins contained in small extracellular vesicles (sEVs), including exosomes, are influenced by UBL3. In this study, we generated transgenic mice expressing biotinylated UBL3 in the forebrain under control of the alpha-CaMKII promoter (Ubl3Tg/+). Western blot analysis revealed that the expression of UBL3 in the cerebral cortex and hippocampus was 6- to 7-fold higher than that in the cerebellum. Therefore, we performed immunoprecipitation of protein extracts from the cerebral cortex of Ubl3+/+ and Ubl3Tg/+ mice using avidin beads to comprehensively discover UBL3 interacting proteins, identifying 35 new UBL3 interacting proteins. Nine proteins were annotated as extracellular exosomes. Gene Ontology (GO) analysis suggested a new relationship between sEVs and RNA metabolism in neurodegenerative diseases. We confirmed the association of endogenous UBL3 with the RNA-binding proteins FUS and HPRT1-both listed in the Neurodegenerative Diseases Variation Database (NDDVD)-and with LYPLA1, which is involved in Huntington's disease, using immunoprecipitation (IP)-western blotting analysis. These UBL3 interacting proteins will accelerate the continued elucidation of sEV research about proteins regulated by novel post-translational modifications by UBL3 in the brain.
  • 上田 洋司, 土田 邦博
    生化学 91(4) 514-518 2019年8月  
    エクソソームを介した疾患増悪蛋白質の伝播は、様々な疾患に関与している。エクソソームに輸送される一連の蛋白質も、リン酸化やアセチル化、ユビキチン化、脂質修飾などの様々な翻訳後修飾が付加される。ユビキチンと相同な配列を持つ蛋白質もまた翻訳後修飾因子として作用し、標的分子の輸送、機能活性調節、分解などに関与している。ユビキチン様蛋白質であるSUMO、ISG15、UBL3によるエクソソームへの制御機構について、近年の知見を含めて紹介した。
  • Hiroshi Ageta, Kunihiro Tsuchida
    Cellular and Molecular Life Sciences 76(24) 4829-4848 2019年7月  査読有り招待有り
  • Keisuke Hitachi, Masashi Nakatani, Akihiko Takasaki, Yuya Ouchi, Akiyoshi Uezumi, Hiroshi Ageta, Hidehito Inagaki, Hiroki Kurahashi, Kunihiro Tsuchida
    EMBO reports 20(3) e47468 2019年3月  査読有り
    Promoter-associated long non-coding RNAs (lncRNAs) regulate the expression of adjacent genes; however, precise roles of these lncRNAs in skeletal muscle remain largely unknown. Here, we characterize a promoter-associated lncRNA, Myoparr, in myogenic differentiation and muscle disorders. Myoparr is expressed from the promoter region of the mouse and human myogenin gene, one of the key myogenic transcription factors. We show that Myoparr is essential both for the specification of myoblasts by activating neighboring myogenin expression and for myoblast cell cycle withdrawal by activating myogenic microRNA expression. Mechanistically, Myoparr interacts with Ddx17, a transcriptional coactivator of MyoD, and regulates the association between Ddx17 and the histone acetyltransferase PCAF Myoparr also promotes skeletal muscle atrophy caused by denervation, and knockdown of Myoparr rescues muscle wasting in mice. Our findings demonstrate that Myoparr is a novel key regulator of muscle development and suggest that Myoparr is a potential therapeutic target for neurogenic atrophy in humans.
  • Hiroshi Ageta, Natsumi Ageta-Ishihara, Keisuke Hitachi, Ozge Karayel, Takanori Onouchi, Hisateru Yamaguchi, Tomoaki Kahyo, Ken Hatanaka, Koji Ikegami, Yusuke Yoshioka, Kenji Nakamura, Nobuyoshi Kosaka, Masashi Nakatani, Akiyoshi Uezumi, Tomihiko Ide, Yutaka Tsutsumi, Haruhiko Sugimura, Makoto Kinoshita, Takahiro Ochiya, Matthias Mann, Mitsutoshi Setou, Kunihiro Tsuchida
    Nature communications 9(1) 3936-3936 2018年9月26日  査読有り
    Exosomes, a type of small extracellular vesicles (sEVs), derived from multivesicular bodies (MVBs), mediate cell-to-cell communication by transporting proteins, mRNAs, and miRNAs. However, the molecular mechanism by which proteins are sorted to sEVs is not fully understood. Here, we report that ubiquitin-like 3 (UBL3)/membrane-anchored Ub-fold protein (MUB) acts as a posttranslational modification (PTM) factor that regulates protein sorting to sEVs. We find that UBL3 modification is indispensable for sorting of UBL3 to MVBs and sEVs. We also observe a 60% reduction of total protein levels in sEVs purified from Ubl3-knockout mice compared with those from wild-type mice. By performing proteomics analysis, we find 1241 UBL3-interacting proteins, including Ras. We also show that UBL3 directly modifies Ras and oncogenic RasG12V mutant, and that UBL3 expression enhances sorting of RasG12V to sEVs via UBL3 modification. Collectively, these results indicate that PTM by UBL3 influences the sorting of proteins to sEVs.
  • Chikako Kimura, Hiroshi Ageta, Hisateru Yamaguchi, Takashi Kuroiwa, Daiki Ikeda, Mitsuhiro Morita, Kazue Hayakawa, Kunihiro Tsuchida, Harumoto Yamada
    Journal of Orthopedic Research and Therapy 7 2017年4月  査読有り
  • Takashi Kuroiwa, Hiroshi Ageta, Daiki Ikeda, Mitsuhiro Morita, Kunihiro Tsuchida, Harumoto Yamada
    Clinics in Surgery 2(1378) 2017年3月  査読有り
  • 黒岩 宇, 上田 洋司, 池田 大樹, 森田 充浩, 土田 邦博, 山田 治基
    日本整形外科学会雑誌 90(8) S1474-S1474 2016年8月  
  • Tsuchida K, Hitachi K, Nakatani M, Uezumi A, Ageta H
    In Myostatin: Structure, Role in Muscle Development and Health Implications, Nova Publishers Chapter 1 1-14 2016年4月  査読有り招待有り
  • L. K. Parajuli, N. Ageta-Ishihara, H. Ageta, Y. Fukazawa, M. Kinoshita
    SEPTINS 136 285-294 2016年  査読有り
  • 土田邦博, 上住聡芳, 中谷直史, 上田洋司, 常陸圭介
    整形・災害外科 58(2) 155-161 2015年2月  
  • 中谷 直史, 上田 洋司, 土田 邦博
    肥満研究 20(Suppl.) 172-172 2014年10月  
  • Daiki Ikeda, Hiroshi Ageta, Kunihiro Tsuchida, Harumoto Yamada
    Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 18(7) 565-72 2013年8月  査読有り
  • 池田 大樹, 上田 洋司, 土田 邦博, 山田 治基
    日本整形外科学会雑誌 86(8) S1259-S1259 2012年8月  査読有り
  • Hiroshi Ageta, Kunihiro Tsuchida
    ACTIVINS AND INHIBINS 85 185-206 2011年  査読有り
  • 上田 洋司, 井ノ口 馨, 土田 邦博
    神経化学 49(2-3) 763-763 2010年8月  
  • Hiroshi Ageta, Shiro Ikegami, Masami Miura, Masao Masuda, Rika Migishima, Toshiaki Hino, Noriko Takashima, Akiko Murayama, Hiromu Sugino, Mitsutoshi Setou, Satoshi Kida, Minesuke Yokoyama, Yoshihisa Hasegawa, Kunihiro Tsuchida, Toshihiko Aosaki, Kaoru Inokuchi
    LEARNING & MEMORY 17(4) 176-185 2010年4月  査読有り
  • Takashi Kitamura, Yoshito Saitoh, Noriko Takashima, Akiko Murayama, Yosuke Niibori, Hiroshi Ageta, Mariko Sekiguchi, Hiroyuki Sugiyama, Kaoru Inokuchi
    CELL 139(4) 814-827 2009年11月  査読有り
  • Kunihiro Tsuchida, Masashi Nakatani, Keisuke Hitachi, Akiyoshi Uezumi, Yoshihide Sunada, Hiroshi Ageta, Kaoru Inokuchi
    CELL COMMUNICATION AND SIGNALING 7 15 2009年6月  査読有り
  • Hiroshi Ageta, Sayaka Asai, Yuki Sugiura, Naoko Goto-Inoue, Nobuhiro Zaima, Mitsutoshi Setou
    MEDICAL MOLECULAR MORPHOLOGY 42(1) 16-23 2009年3月  査読有り
  • Hyunjeong Yang, Hiroshi Takagi, Yoshiyuki Konishi, Hiroshi Ageta, Koji Ikegami, Ikuko Yao, Showbu Sato, Ken Hatanaka, Kaoru Inokuchi, Dae-Hyun Seog, Mitsutoshi Setou
    PLOS ONE 3(7) e2809 2008年7月  査読有り
  • Hiroshi Ageta, Akiko Murayama, Rika Migishima, Satoshi Kida, Kunihiro Tsuchida, Minesuke Yokoyama, Kaoru Inokuchi
    PLOS ONE 3(4) e1869 2008年4月  査読有り
  • Yoko Shoji-Kasai, Hiroshi Ageta, Yoshihisa Hasegawa, Kunihiro Tsuchida, Hiromu Sugino, Kaoru Inokuchi
    JOURNAL OF CELL SCIENCE 120(21) 3830-3837 2007年11月  査読有り
  • Ikuko Yao, Hiroshi Takagi, Hiroshi Ageta, Tomoaki Kahyo, Showbu Sato, Ken Hatanaka, Yoshiyuki Fukuda, Tomoki Chiba, Nobuhiro Morone, Shigeki Yuasa, Kaoru Inokuchi, Toshihisa Ohtsuka, Grant R. MacGregor, Keiji Tanaka, Mitsutoshi Setou
    CELL 130(5) 943-957 2007年9月  査読有り
  • 瀬藤 光利, 上田 洋司, 杉浦 悠毅, 新間 秀一
    福島医学雑誌 57(1) 70-71 2007年3月  
  • I. Yao, H. Takagi, H. Ageta, T. Kahyo, S. Sato, K. Hatanaka, Y. Fukuda, T. Chiba, N. Morone, S. Yuasa, K. Inokuchi, T. Ohtsuka, G.R. MacGregor, K. Tanaka, M. Setou
    Cell 131(1) 190- 2007年  査読有り
  • 上田 洋司, 右島 理可, 茂手木 淑子, 日野 敏昭, 高部 美穂, 喜田 聡, 杉野 弘, 土田 邦博, 横山 峯介, 井ノ口 馨
    神経化学 43(2-3) 554-554 2004年8月  
  • H Ageta, A Kato, Y Fukazawa, K Inokuchi, H Sugiyama
    MOLECULAR BRAIN RESEARCH 97(2) 186-189 2001年12月  査読有り
  • H Ageta, A Kato, S Hatakeyama, K Nakayama, Y Isojima, H Sugiyama
    JOURNAL OF BIOLOGICAL CHEMISTRY 276(19) 15893-15897 2001年5月  査読有り

MISC

 23

書籍等出版物

 7

講演・口頭発表等

 17

共同研究・競争的資金等の研究課題

 18

社会貢献活動

 2

メディア報道

 18